Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice

Imatinib (IM) treatment efficacy in 116 chronic myeloid leukemia (CML) patients in different studies was analyzed. Patient group was non‑selective with prospective enrollment. The study was based on real‑time patient’s register allows to treatment quality control due to clinical results. Cytogenetic response (CO), hematological data, and overall survival (OS) were used as criteria for the therapy efficacy. After 12 month of treatment in 46.4 % of CML patients in early chronic phase complete CO (CCO) was obtained, in 33.3 % — in the late chronic phase, and in 13.3 % — in accelerated phase. Deficit of daily imatinib dose and intervals in treatment schedule were made a negative influence on CO quality. The median of OS was 120 months.

1. Vysotskaya L.L., Golenkov A.K., Trifonova E.V. et al. Efficacy of the expanded treatment program with imatinib mesylate in 109 patients with chronic myeloid leukemia (CML) — EHA‑haematologica. Hematol 2007;532:abstr. 1496.

2. Gambacorti C., Talpaz M., Sawyers C. et al. Five year follow‑up results of a phase II trial in patients with late chronic phase chronic myeloid leukemia treated with Imatinib who are refractory/intolerant of interferon alfa. Blood 2005;106:317а. Abstr. 1089.

3. Cervantes F., Hernandez‑Boluda J.C., Steegmann G.L. et al. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression — free survival in 150 patients. Haematol 2003;88:1117−22.

4. Hughes T.P., Kaeda J., Branford S. et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423−32.

5. Baccarani M., Gilhot F., Larson R.A. et al. Outcomes by cytogenetic and molecular response at 12 and 18 months of imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) in the IRIS trial [abstract]. Blood 2006;108:abstr. 2138.

6. Cortes J., Talpaz M., O’Brien S. et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Сlin Cancer Res 2005;11:3425−32.

7. Kantarjian H.M., O’Brien S., Cortes J.E. et al. Treatment of Philadelphia chromosomepositive, accelerated — phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002;8(7):2167−76.

8. Lahaye N., Riehm B., Berger U. et al. 4,5 year follow‑up of response and resistance in 300 patients with BCR‑ABL positive leukemias treated with imatinib in a single center. Cancer 2005;103:1659−69.

9. Голенков А.К., Высоцкая Л.Л., Трифонова Е.В., Гуров А.Н. Организационные и клинические аспекты лечения хронического миелолейкоза гливеком в широкой клинической практике. Вестн гематол 2008;4(4):29−32.

10. Высоцкая Л.Л., Трифонова Е.В., Голенков А.К. Эффективность лечения хронического иелолейкоза гливеком в широкой клинической практике. Гематол и трансфузиол 2008;53(6):17−22.

11. Druker B.J., Guilhot F., O’Brien S.G. et al. Five year follow‑up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408.

12. Kantarjian H.М., Talpaz M., O’Brien S.G. et al. Survival benefit with imatinib mesylate versus interferon-alphabased regimens in newly diagnosed chronicphase chronic myelogenous leukemia. Blood 2006;108:1835−40.

13. Куцев С.И., Оксенюк О.С., Кравченко Е.Г. и др. Лекарственный мониторинг терапии хронического миелолейкоза иматинибом. Клин онкогематол 2010; 3(1):1−9.

14. O’Brien S.G., Guilhot F., Goldman J. et al. International randomised study of interferon versus STI571 (IRIS) 7‑year follow‑up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML‑CP) treated with imatinib (IM). Blood 2008; 112(11):6. Abstr. 186.

15. Kantarjian H.М., O’Brien S.G., Jabbour E. et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012; 119(9):1981−7.